Search For "mild"
Rajinikanth wishes singer SP Balasubrahmanyam a speedy recovery, shares vi
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], August 17 (ANI): Superstar Rajinikanth on Monday wished a speedy recovery to singer SP Balasubrahmanyam after the latter was tested positive for COVID-19 with 'mild' symptoms.
Read More
Fusion Health Care launches COVID-19 drug Favipiravir and an immunity boos
Updated : 5 years, 7 months ago IST
Hyderabad (Telangana) [India], Aug 17 (ANI/BusinessWire India): Fusion Health Care Pvt Ltd, a leading innovative pharmaceutical company based at Hyderabad, has announced the launch of its Favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.
Read More
SP Balasubrahmanyam's condition stable, says hospital authorities
Updated : 5 years, 7 months ago IST
Chennai (Tamil Nadu) [India], August 6 (ANI): The condition of playback singer SP Balasubrahmanyam, who was recently tested positive for COVID-19 with 'mild' symptoms, is stable and is maintaining normal oxygen saturations, the hospital authorities said.
Read More
Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce th
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India] Aug 6 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that it will introduce a 400 mg version of oral antiviral FabiFlu®, for the treatment of mild to moderate COVID-19 in India.
Read More
Glenmark introduces higher strength of FabiFlu to reduce pill burden of Co
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 6 (ANI): Glenmark Pharmaceuticals will introduce a 400 mg version of oral anti-viral FabiFlu for the treatment of mild to moderate Covid-19 in India.
Read More
Singer SP Balasubrahmanyam tests positive for COVID-19
Updated : 5 years, 7 months ago IST
New Delhi [India], Aug 5 (ANI): Playback singer S P Balasubrahmanyam on Wednesday confirmed testing positive for COVID-19 with 'mild' symptoms.
Read More
Lupin launches Favipiravir in India for COVID treatment at Rs 49 per table
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 5 (ANI): Pharma major Lupin Ltd on Wednesday announced the launch of Favipiravir in India under the brand name Covihalt for treatment of mild to moderate COVID-19.
Read More
NIH launches clinical trial in US to test potential therapeutics for mild,
Updated : 5 years, 7 months ago IST
Washington D.C. [US], Aug 5 (Xinhua/ANI): The U.S. National Institutes of Health (NIH) said on Tuesday a Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies
Read More
Sun Pharma launches Favipiravir in India for Rs 35 per tablet
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 4 (ANI): Sun Pharmaceutical Industries said on Tuesday it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
Read More
Converge Biotech announces the launch of Vergiflu (Favipiravir 200 mg) in
Updated : 5 years, 7 months ago IST
Hyderabad (Telangana) [India] Aug 4 (ANI/BusinessWire India): Converge Biotech, a leading healthcare company based at Hyderabad, today announces the launch of generic Favipiravir tablet in India.
Read More
Centralised system to classify COVID-19 infected persons: K'taka Medical E
Updated : 5 years, 7 months ago IST
Bengaluru (Karnataka) [India], July 29 (ANI): There will be a centralised system in place in Karnataka to classify asymptomatic, symptomatic and mild symptomatic persons and recommend treatment based on the severity of the cases, said Medical Education Minister Dr K Sudhakar on Tuesday here.
Read More
Mildly symptomatic COVID patients to be admitted in Category II, III hospi
Updated : 5 years, 7 months ago IST
Srinagar (Jammu and Kashmir) [India], July 28 (ANI): The Jammu and Kashmir Government on Tuesday said that COVID-19 patients with mild and moderate level hospitals should be admitted into category II/III hospitals at the sub-district/district level.
Read More